第二项主要研究确定每六个月进行一次艾滋病毒预防注射(lenacapavir),对不同人口有效,为监管批准铺平了道路。 2nd major study establishes six-monthly HIV prevention injection, lenacapavir, effective for diverse populations, paving way for regulatory approval.
第二项主要研究,即PURPOSE 2,证实了每六个月一次的艾滋病毒预防注射(lenacapavir)对不同人口,包括变性人和变性人的有效效果。 A second major study, PURPOSE 2, has confirmed the effectiveness of a six-monthly HIV prevention injection, lenacapavir, for diverse populations, including cisgender and transgender individuals. 注射在艾滋病毒/R4P会议上展示了高疗效,与避孕药相比,大大降低了艾滋病毒感染。 Presented at the HIVR4P conference, the injection demonstrated high efficacy, significantly reducing HIV infections compared to pills. Gilead Science计划寻求对lenacapavir的监管批准,作为一项预防措施,尽管其高成本给低收入国家带来了负担能力的挑战。 Gilead Sciences plans to seek regulatory approval for lenacapavir as a preventive measure, although its high cost poses affordability challenges for low-income countries.